Your fact-checks will appear here
A type of breast cancer that is aggressive and has limited treatment options.
Two clinical studies are publicly associated with testing , but only one—the phase I/II trial NCT05318469—has detailed, actively reported design elements: it combines oral ivermectin with an anti‑PD‑1...
Two registered early‑phase clinical trials combine ivermectin with immune checkpoint inhibitors for cancer: a phase I/II investigator‑initiated trial testing oral ivermectin with balstilimab (and an e...
Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...
A single actively registered clinical trial testing has been identified: a Phase I/II study (NCT05318469) combining oral ivermectin with anti‑PD‑1 immune checkpoint therapy for (mTNBC), and its primar...
There are no registered large-scale randomized controlled trials (phase III or higher) planned or listed in the provided reporting that test ; the only clearly documented human studies are early-phase...
Published results for NCT05318469 are limited to conference abstracts and trial summaries that report tolerability and early activity signals: an ASCO/Journal of Clinical Oncology abstract states the ...
There is evidence of a small number of early‑phase clinical trials testing ivermectin in cancer patients, but they are limited in number, mostly based in the United States, and focused on combination ...
As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...